Vascular endothelial growth factor (VEGF) plays important roles in a wide variety of physiological processes, some reflecting its role in promoting angiogenesis and others important for normal physiological functions, such that issues of safety are of particular concern for long-term therapies premised on its inhibition. Physiological VEGF expression is now known to be important for protection of hepatocytes[@b1] and renal cells,[@b2] [@b3] for wound healing,[@b4] [@b5] female reproductive cycling,[@b6] [@b7] bone growth,[@b6] [@b8] trophic maintenance of capillaries[@b9] and neurons.[@b10] In the eye, VEGF plays a physiological role in the development and trophic maintenance of the choriocapillaris[@b11] [@b12] and in protecting retinal neurons from apoptosis in conditions of ischaemia.[@b13] [@b14] The systemic use of bevacizumab (Avastin), a humanised antibody blocking all VEGF isoforms, in cancer treatment regimens has been accompanied by increased incidences of systemic hypertension, bleeding, proteinuria, gastrointestinal perforations and thromboembolic events.[@b15]^--^[@b17] While the intravitreous mode of administration of anti-VEGF agents would be expected to reduce the severity of these systemic events, potential concerns remain, given the systemic levels, observed response in the fellow eye after intravitreous administration and the long-term maintenance therapy that some patients may require.[@b18] [@b19]

Preclinical findings in animal models have suggested that the selective inhibition by intravitreous pegaptanib, which targets VEGF~165~, an especially proinflammatory isoform,[@b22]^--^[@b21] and spares VEGF~120~, could minimise some of the safety issues. While providing clinical benefit in the treatment of all angiographic subtypes of neovascular age-related macular degeneration (NV-AMD),[@b23] [@b24] continuous intravitreous pegaptanib sodium has been shown to have an excellent safety profile over 2 years.[@b23] [@b25] We now present further data for patients who have continued for 3 years in the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial, showing that no new safety signals have emerged over this additional period.

MATERIALS AND METHODS {#s2}
=====================

Study design {#s2a}
------------

The details of the design of the VISION trial have been reported.[@b23] [@b25] The study protocol was reviewed and approved by an institutional review board at each study site in accordance with the guidelines for the conduct of clinical research in the 1964 Declaration of Helsinki. Study participants provided signed informed consent before baseline procedures were performed. In brief, two identically designed, phase 3, prospective, comparative studies comprised the trial; both had randomised, double-masked, controlled, dose-ranging, multicentre, parallel-group designs ([fig 1](#BJ1-92-12-1606-f01){ref-type="fig"}). At baseline, patients were randomised to one of four treatment groups (0.3 mg, 1 mg or 3 mg of pegaptanib sodium in 0.09 ml of solution or sham injections) and received nine intravitreous or sham injections once every 6 weeks for 48 weeks with follow-up to week 54. At week 54, subjects in the active therapy arms were rerandomised (1:1) to either discontinue or continue treatment for a further 48 weeks (eight injections). Subjects receiving sham were rerandomised at week 54 (1:1:1:1:1) to discontinue sham treatment, to continue on the study receiving one of the three active treatments or to continue on sham therapy.

![Randomisation at years 1, 2 and 3.](BJ1-92-12-1606-f01){#BJ1-92-12-1606-f01}

At 102 weeks, 422 remaining subjects with visual acuity in the study eye of 20/800 or better continued treatment for a further nine injections in the third year (week 102 to week 150 with follow-up to week 156). Those receiving the 0.3 mg or 1 mg dose in year 2 continued on the same treatment, while subjects receiving the 3 mg dose or sham were rerandomised to 0.3 mg or 1 mg (1:1). Subjects not on treatment during the second year but who had received 0.3 mg or 1 mg during the first year resumed treatment at the previous dose. Subjects not on treatment during year 2 but who had received 3 mg or sham during year 1 were rerandomised to receive 0.3 mg or 1 mg (1:1). In year 3, study participants were masked to the actual dose being administered but were aware that only active 0.3 mg and 1 mg doses were being administered.

Clinical monitoring {#s2b}
-------------------

Throughout the study, safety was assessed by adverse event reporting, ophthalmic examination, applanation tonometry, laboratory assessments, electrocardiograms (ECGs) and vital signs. Laboratory tests included haematology (complete blood counts) and chemistry (electrolytes, renal and hepatic) assessments. Adverse events were assessed by investigators for the relationship to the injection procedure and to study the drug.

Independent data monitoring {#s2c}
---------------------------

An Independent Data Monitoring Committee consisting of experts independent from the sponsors and the investigators was established before the trial's start. The committee reviewed the data and procedures of both studies on an ongoing basis to ensure subject safety.

End points and analyses {#s2d}
-----------------------

Safety end-points included all adverse events and serious adverse events (ophthalmic or systemic), intraocular pressure (IOP), clinical laboratory data, ECG abnormalities and changes, and loss of \>20 letters (four lines; Early Treatment of Diabetic Retinopathy Study) of visual acuity between visits. Adverse events were coded according to the Medical Dictionary for Regulatory Activities 5.1. If the subject experienced more than one occurrence of the same event, only the event with the highest severity value was counted.

Safety data were tabulated for the combined population of the two studies, and year 3 adverse events were those with an onset date from week 102 (including the injection day at week 102) up to week 156 (excluding the injection day at week 156). Unless otherwise specified, the safety population included all subjects who received active pegaptanib sodium therapy at any dose throughout years 1, 2 and 3. Analyses of injection-related serious adverse events included all subjects who received pegaptanib sodium in year 3 regardless of previous randomised treatment (ie, sham or treatment discontinued). Assessments of IOP changes were performed in subjects who received 0.3 mg or 1 mg of pegaptanib sodium continuously from years 1 to 3. Statistical analyses on year 3 data were limited by small sample sizes and were considered to be descriptive.

RESULTS {#s3}
=======

In all, 165 subjects who received active therapy with pegaptanib sodium in the first 2 years of the study were rerandomised at week 102. The rerandomised population was predominantly white with a higher ratio of females to males and a mean age in the mid-70s. Patient groups generally were similar to those reported at 54 and 102 weeks.[@b25]^--^[@b24] The primary safety population consisted of the 161 subjects who received at least one dose of study medication in year 3 (75 received 0.3 mg, and 86 received 1 mg; four patients were randomised but did not receive study medication) and who received active treatment throughout years 1 and 2. The total number of injections administered in these 161 subjects during year 3 was 1254 (mean injections per patient = 7.8). In all, 422 subjects received a total of 3227 injections of pegaptanib sodium 0.3 mg or 1 mg in year 3 regardless of treatment in previous years.

As seen in years 1 and 2, pegaptanib sodium was well tolerated in year 3, and adverse events were mainly ocular in nature, mild and predictable. Ocular adverse events occurred in 114/161 (71%) subjects in the primary safety population in year 3, and the majority of events were associated with the injection procedure ([table 1](#BJ1-92-12-1606-t01){ref-type="table"}). Twenty-seven (17%) subjects experienced serious ocular or non-ocular adverse events, and 3% discontinued due to an adverse event.

###### Adverse event summary, study eye (year 3 safety population) (n (%))

                                                    All subjects who received active therapy for 3 years n = 161
  ------------------------------------------------ --------------------------------------------------------------
  Subjects with any adverse event                                             142 (88)
  Subjects with an ocular adverse event                                       114 (71)
      Injection-procedure related                                             84 (52)
      Study-therapy related                                                   19 (12)
  Subjects with any serious adverse event                                     27 (17)
  Subjects discontinuing due to an adverse event                               5 (3)

Ocular adverse events reported in study eyes in ⩾5% of the primary safety population subjects are summarised in [table 2](#BJ1-92-12-1606-t02){ref-type="table"}. The most common ocular adverse events were punctate keratitis (41/161 (25%)), increased IOP (32/161 (20%)), eye pain (27/161 (17%)), and cataract (23/161 (14%)). The incidence of these events was similar to or less than the incidence in years 1 and 2 of the study. As in previous years, no severe anterior chamber inflammation was seen, and the assessment of cataract in phakic subjects did not suggest that pegaptanib sodium injections were associated with cataract progression. During the third year, 8/161 (5%) subjects lost 20 or more letters of vision, and five of these fully or partially improved in subsequent visits.

###### Adverse events reported in study eyes in ⩾5% of subjects (year 3, safety population) (n (%))

  Adverse event                     All subjects who received active therapy for 3 years n = 161
  -------------------------------- --------------------------------------------------------------
  Punctate keratitis                                          41 (25)
  Intraocular pressure increased                              32 (20)
  Eye pain                                                    27 (17)
  Cataract                                                    23 (14)
  Vitreous floaters                                           18 (11)
  Conjunctival haemorrhage                                     15 (9)
  Anterior chamber inflammation                                14 (9)
  Corneal oedema                                               13 (8)
  Vitreous opacities                                           13 (8)
  Visual acuity reduced                                        10 (6)
  Eye pruritus                                                 8 (5)
  Lacrimation increased                                        8 (5)

Injection-related serious adverse events were rare in the 422 subjects treated with pegaptanib sodium 0.3 mg or 1 mg in year 3, regardless of treatment in previous years ([table 3](#BJ1-92-12-1606-t03){ref-type="table"}). Two cases of endophthalmitis (0.06% per injection, 0.47% per patient), one case of rhegmatogenous retinal detachment (0.03% per injection, 0.24% per patient) and no cases of traumatic cataract were reported. One case of vitreous haemorrhage was reported as a serious ocular adverse event and was assessed by the investigator to be related to the injection procedure. One reported event of reduced visual acuity of at least four lines between two consecutive visits (experienced by a subject who also had experienced endophthalmitis) was assessed to be related to the injection procedure. In addition, one subject experienced retinal haemorrhage and vitreous haemorrhage that were assessed to be related to the study drug, but not reported as a serious ocular adverse event.

###### Serious ocular adverse events reported in study eyes (year 3) (number of cases (rate per injection))

  Adverse event                        All subjects who received pegaptanib sodium 0.3 mg or 1 mg in year 3 n = 422 (no of injections = 3227)
  ----------------------------------- --------------------------------------------------------------------------------------------------------
  Endophthalmitis                                                             2 (0.06% per injection)
  Rhegmatogenous retinal detachment                                           1 (0.03% per injection)
  Traumatic cataract                                                           0 (0.0% per injection)
  Vitreous haemorrhage                                                        1 (0.03% per injection)

The general pattern of IOP changes seen in years 1 and 2 continued in year 3. On average, subjects experienced an increase in IOP at the 30 min postinjection assessment compared with preinjection at each treatment visit. At the 1-week postinjection assessment, the pressure had returned to levels similar to preinjection. Of subjects treated with 0.3 mg or 1 mg of pegaptanib sodium continuously for 3 years, the mean IOP remained stable throughout the 3 years, and more than 80% of subjects did not experience IOP values ⩾35 mm Hg at any time. Intervention for increased IOP on injection days also was relatively infrequent. Ten of 109 (9%) underwent paracenteses, and only 17 (16%) required treatment with concomitant medications for increased IOP on one or more injection days during the 3-year follow-up.

The Independent Reading Center graded all baseline and week 30, 54, 78, 102 and 156 fluorescein angiograms. These examinations revealed no retinal vascular abnormalities that are unexpected in the natural history of NV-AMD. Specifically, there were no notable delays in arteriovenous transit time, or abnormalities in choroidal perfusion or arteriolar occlusions.

As in years 1 and 2, no evidence of systemic safety signals related to the inhibition of VEGF arose with the third year of administration of pegaptanib sodium. In the 161 subjects receiving active therapy for 3 years, the most common nonocular adverse events in year 3 were infections and infestations (18%); respiratory, thoracic and mediastinal disorders (15%); and gastrointestinal disorders (14%) ([table 4](#BJ1-92-12-1606-t04){ref-type="table"}). There were no thromboembolic cerebrovascular accidents; only two subjects had an event of myocardial infarction (2%), and one subject had an event of angina (1%). The incidence of these thromboembolic events was the same among the entire cohort of 422 subjects treated with pegaptanib sodium in year 3 and was similar to those observed in the pegaptanib and sham groups in years 1 and 2. There were no serious nonocular haemorrhagic events. Among the entire cohort of 422 subjects treated with pegaptanib sodium in year 3, the most frequently occurring serious adverse events were neoplasms and cardiac disorders, each experienced by 12 subjects (3%); gastrointestinal disorders (10 subjects, 2%); and vascular disorders (nine subjects, 2%). With the exception of one event of hypertension that the investigator assessed to be related to the injection procedure (the event occurred before an injection, and the investigator considered that the event was due to the subject's emotions in connection with the subsequent injection), none of these events was related to the injection procedure or the study drug. There were six deaths (1%) among the 422 subjects who received pegaptanib sodium in year 3; none of the deaths was considered to be related to study drug or injection procedure by the investigator. The adverse events associated with these death cases were glioblastoma, cardiac arrest, *Clostridium* colitis, cardiorespiratory arrest, hypotension and metastatic lung cancer, one case each.

###### All-causality non-ocular adverse events in ⩾5% of subjects (year 3, safety population) (n (%))

  Adverse event (system organ class)                 All subjects who received active therapy for 3 years n = 161
  ------------------------------------------------- --------------------------------------------------------------
  Investigations\*                                                             41 (25)
  Infections and infestations                                                  29 (18)
  Respiratory, thoracic and mediastinal disorders                              24 (15)
  Gastrointestinal disorders                                                   23 (14)
  Musculoskeletal and connective tissue disorders                              20 (12)
  Nervous system disorders                                                     18 (11)
  Cardiac disorders                                                            17 (11)
  Injury, poisoning and procedural complications                               16 (10)
  Vascular disorders                                                            15 (9)
  Skin and subcutaneous tissue disorders                                        14 (9)
  Metabolism and nutrition disorders                                            10 (6)
  Neoplasms benign, malignant and unspecified                                   9 (6)

\*The majority of these events were "increased intraocular pressure (IOP)"; the investigators were required to report an IOP of ⩾30 mm Hg at 30 min after injection as an adverse event.

There were no findings in relation to vital signs performed at each clinical assessment or ECG test results that were suggestive of a relationship to treatment with pegaptanib sodium; in particular, there was no evidence of an increase in mean blood pressure over the 3 years of treatment ([fig 2](#BJ1-92-12-1606-f02){ref-type="fig"}). There were no laboratory test findings suggestive of a relationship with pegaptanib sodium. Specifically, when the median change from baseline was reviewed for the laboratory parameters, there was no evidence of a clinically meaningful pattern. Additionally, analysis of clinically significant laboratory abnormalities for individual patients revealed the majority to be transient, with no findings to suggest a relationship between treatment with pegaptanib sodium and these abnormalities.

![(A) Mean blood pressure through 3 years: subjects who received 0.3 mg of pegaptanib sodium for all 3 years, n = 52. (B) Mean blood pressure through 3 years: subjects who received 1 mg of pegaptanib sodium for all 3 years, n = 57.](BJ1-92-12-1606-f02){#BJ1-92-12-1606-f02}

DISCUSSION {#s4}
==========

The data from the VISION trial demonstrate a favourable ocular and systemic safety profile for 3 years of continuous selective VEGF inhibition with pegaptanib sodium for the treatment of NV-AMD. No new safety signals emerged during the third year of therapy with pegaptanib sodium. Subjects' compliance with intravitreal injections of pegaptanib sodium during the third year also was consistent with the previous 2 years of the study.

There was no change in the ocular safety profile of pegaptanib sodium in the third year. In year 3, as in the previous years, adverse events were mainly ocular in nature, mild, transient and related to the injection procedure. The incidence of the most commonly reported ophthalmic adverse events (eg, punctate keratitis, eye pain, vitreous floaters and cataract) decreased during the second[@b25] and third years of the studies. While there was no sham group in the third year of the study, the most common ocular events in years 1 and 2 were reported in a higher proportion of study eyes of sham patients relative to the fellow eyes of each active treatment group, suggesting that many of these events may be related to the preparation procedure for the intravitreous injection rather than to the intravitreous injection itself. There was no case of severe anterior chamber inflammation, which suggests that no significant intraocular activation of the immunological response was triggered. This was consistent with previous studies that employed an aptamer for therapy[@b26] and with those demonstrating an absence of detectable serum antibodies against pegaptanib.[@b27] Although extremely rare cases of anaphylactoid reactions have been reported in patients receiving pegaptanib (Macugen (package insert). New York: (OSI) Eyetech; 2006), it is not clear if the response is triggered by pegaptanib or some other component of the preparation or procedure. Additionally, there was no evidence of a difference in cataract progression between the third year and previous years. No unexpected changes in the choroidal and retinal vasculatures were seen even after 3 years of selective VEGF inhibition.

The low rate of serious ocular events continued during study year 3, with the incidence of rhegmatogenous retinal detachment only 0.03% per injection (1/3227), and no iatrogenic traumatic cataracts were reported. The rate of endophthalmitis continued to decline over the course of the studies from 0.16% per injection (12 of 7545 injections) in the first year to 0.10% per injection (4/4091) in the second year[@b25] and to 0.06% per injection (2/3227) in the third year (p\<0.0001, Cochran--Armitage trend test). This decrease in the rate of endophthalmitis may result at least partially from a protocol amendment emphasising the importance of adherence to aseptic technique when performing intravitreal injections. The lower rate of endophthalmitis also may be attributed to the widespread adoption of and increasing familiarity with intravitreous injections by retina specialists over the 3 years of this study.

There was also no change in the systemic safety profile of pegaptanib sodium. The types and incidence of systemic serious adverse events observed are not unexpected in this elderly patient population, and none of these events was judged to be related to study drug. This favourable systemic safety profile is of particular importance for the NV-AMD population that is at higher risk for cardiovascular and thromboembolic diseases.[@b28] In conclusion, 3 years of continuous selective VEGF inhibition with pegaptanib sodium in the treatment of patients with NV-AMD confirmed the favourable safety profile of pegaptanib sodium.
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